Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CEO and Chairman

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2022-03-15	Premium	sold	Premium	Premium	Premium	-
2021-03-23	Premium	acquired	Premium	Premium	Premium	-
2021-03-23	Premium	bought	Premium	Premium	Premium	-
2021-03-23	Premium	acquired	Premium	Premium	Premium	-
2021-03-23	Premium	bought	Premium	Premium	Premium	-
2021-03-23	Premium	bought	Premium	Premium	Premium	-
2021-03-23	Premium	acquired	Premium	Premium	Premium	-
2021-03-23	Premium	acquired	Premium	Premium	Premium	-
2021-03-23	Premium	bought	Premium	Premium	Premium	-
2021-03-23	Premium	bought	Premium	Premium	Premium	-
2021-03-23	Premium	acquired	Premium	Premium	Premium	-
2021-03-23	Premium	acquired	Premium	Premium	Premium	CEO and Chairman
2021-03-23	Premium	bought	Premium	Premium	Premium	CEO and Chairman

TIL - Instil Bio, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for TIL